Long-Read HLA Typing Sample Requirements

At a glance:

• Quick answer: what samples can be considered for long-read HLA typing?
• Long-read HLA typing sample requirements by sample type
• Why DNA quality matters for long-read HLA typing
• FFPE blocks: can CD Genomics perform DNA extraction?
• T cells, organoids, and cell pellets: what should researchers prepare?
• Whole blood and cohort samples
• What information is needed before requesting a quote?
• Common sample-submission mistakes
• Research-use-only limitations
• FAQ
• Next steps
• Author

Many long-read HLA typing quote requests stall for one simple reason: the service team can't confirm feasibility until they understand what sample you actually have, whether genomic DNA is already extracted, and how many samples you plan to submit.

Direct answer (read this first): the most straightforward input for long-read HLA typing is high-quality extracted genomic DNA. However, whole blood, cell pellets (including T cells), tissue-derived samples, frozen organoid pellets, and even FFPE blocks may be considered—but they usually require a feasibility review to decide (1) whether DNA extraction is needed and can be performed, and (2) whether the resulting DNA integrity is likely to support the requested HLA loci and resolution.

If you want a fast, actionable quote, send: sample type, sample number, requested HLA loci, desired resolution, DNA availability, and extraction needs—plus any DNA QC you already have.

Quick answer: what samples can be considered for long-read HLA typing?

Answer: Yes—multiple sample types can be considered, but they're not equally "quote-ready." Extracted genomic DNA is usually the clearest starting point because it reduces uncertainty around extraction yield and integrity. Whole blood, tissues, cell pellets, and organoid pellets can also work if DNA extraction is planned and the integrity supports long-read sequencing. FFPE blocks are the highest-risk category because fixation commonly fragments and chemically modifies DNA, and long-read workflows are particularly sensitive to that damage.

Long-read HLA typing is often used specifically because HLA loci are highly polymorphic and benefit from long-range information (for example, phasing across multiple variant sites). Reviews of long-read HLA methods discuss this value in the context of nanopore sequencing, including typical technical constraints and error considerations (see "A long road/read to rapid high-resolution HLA typing" (2020, PMC)).

That's why the "best" sample is not just the one that is easiest to ship—it's the one that is most likely to yield DNA with sufficient integrity for your target HLA loci and your desired resolution.

Definitions (to prevent quote confusion):

• Extracted genomic DNA: purified DNA already isolated from your sample (blood/cells/tissue), typically quantified and optionally QC-tested.
• Whole blood: unprocessed blood in a collection tube (tube type and handling conditions matter).
• Cell pellet: concentrated cells collected by centrifugation (e.g., a T-cell pellet). Often shipped frozen.
• Organoid pellet: concentrated organoid cells (and sometimes residual matrix) collected and frozen.
• FFPE block: formalin-fixed, paraffin-embedded tissue block. Excellent for histology, often challenging for long-range DNA work.

Long-read HLA typing sample planning depends on DNA availability, sample preservation, and requested resolution.

Table 1. Sample type → feasibility questions → what to provide for a quote

Use this table as a pre-quote checklist: pick your row, answer the feasibility questions in one email, and attach any QC you already have. The faster the team can decide "extract vs. don't extract" and "likely vs. unlikely to meet integrity needs," the faster you get a reliable quote.

Long-read HLA typing sample requirements by sample type

Answer: when you strip away the platform details, most feasibility decisions come down to two questions:

1. Can we obtain genomic DNA with sufficient integrity from this sample type?
2. Do we have enough context (metadata + QC) to scope the requested loci and reporting?

The sections below walk through each sample category with an answer-first format, focusing on what typically blocks quotes and how to unblock them.

Why DNA quality matters for long-read HLA typing

Answer: long-read HLA typing depends on DNA integrity because long reads (or long-range amplicons) help resolve allelic ambiguity and phase variants across highly polymorphic HLA loci. Fragmented DNA narrows the achievable read length and can reduce the likelihood of spanning the informative regions needed for high-resolution calls.

Why HLA is hard: polymorphism + similarity + phasing

The HLA system sits within the major histocompatibility complex (MHC), one of the most polymorphic regions of the human genome. The non-commercial IPD-IMGT/HLA resource at EMBL-EBI describes the MHC as "hyperpolymorphic" and emphasizes that HLA allele variation is not just single variants—it's phased sequence patterns across a locus (see IPD-IMGT/HLA genomics notes).

This is a major reason HLA typing is technically different from routine variant calling. A short-read approach may observe variant sites but struggle to determine which variants belong together on the same chromosome (phase). Long-read strategies can help by spanning more of the locus, but that benefit is only realized when the input DNA supports long-range information.

Oxford Nanopore vs PacBio SMRT: why integrity rules both

Answer: for both oxford nanopore hla typing and PacBio SMRT-based approaches, DNA integrity is a first-order variable: fragmented or chemically damaged DNA can limit the achievable span across an HLA locus, which can reduce phasing power and increase ambiguity.

This is consistent with broader long-read guidance: a peer-reviewed review in Molecular Ecology Resources states that long-read sequencing experiments demand highly purified high-molecular-weight (HMW) DNA (see Wahab et al., 2022, PubMed).

What "DNA quality" means in long-read projects

For quote readiness, "DNA quality" usually means you can describe (even approximately):

• Integrity / fragment size distribution (are there intact long molecules or is the DNA mostly short?)
• Purity (are inhibitors likely present?)
• Handling history (how many freeze-thaws, storage conditions)

Key Takeaway: For long-read HLA typing, the limiting factor is often DNA integrity, not just total DNA quantity.

FFPE blocks: can CD Genomics perform DNA extraction?

Answer: FFPE blocks may be considered, and DNA extraction may be possible, but acceptance and success cannot be assumed. FFPE introduces DNA fragmentation and chemical damage that can limit long-range amplification and long-read performance. For FFPE submissions, the right expectation is: feasibility review + possible pilot extraction/QC step, then decide whether the requested HLA loci/resolution are realistic from that material.

Why FFPE is challenging for long-read work

FFPE processing is known to create multiple failure modes:

• Fragmentation (shorter templates)
• Crosslinks (reduced amplifiability)
• Damage artifacts (including deamination-associated changes)

Evidence-based guidance from the U.S. National Cancer Institute emphasizes that pre-analytical factors (fixation conditions, processing, storage) strongly affect nucleic acid quality (see NCI Biospecimen Evidence-Based Practices, 2018, PMC).

What to provide if you want an FFPE-based quote

Because FFPE quality varies dramatically across institutions and blocks, quote readiness depends on the context you provide:

• Approximate block age and storage conditions
• If known: fixation type and duration (overfixation is a common risk)
• Tissue type, and whether tumor content matters for your RUO study
• Whether you can provide sections/slides for a pilot QC

⚠️ Warning: If your project requires long contiguous coverage across HLA loci, FFPE-derived DNA may not meet integrity needs. Treat FFPE as "review required," not "standard input."

T cells, organoids, and cell pellets: what should researchers prepare?

Answer: cell-derived samples can be suitable, but quote readiness depends on whether DNA extraction is required, whether the material is clean and well-documented, and whether handling preserves DNA integrity. Because exact cell input needs vary by workflow and locus strategy, do not assume a universal cell-number requirement—confirm with the CD Genomics service team during feasibility review.

T cell samples

Answer: T cells can be considered when the project design specifically needs a defined immune cell population, but you should document purity and processing history.

What matters operationally:

• Was it an enriched T-cell fraction or a mixed PBMC fraction?
• Were cells activated, fixed, or otherwise processed in a way that could impact DNA extraction?
• Was the pellet frozen promptly and kept cold-chain stable?

What to send with the sample:

• Cell type (e.g., CD3+ T cells) and enrichment method (if any)
• Sample count and whether this is paired with another cell type
• Any known contamination risk (e.g., co-culture)

Frozen organoid pellets

Answer: frozen organoid pellets can be considered, but they often come with "hidden variables" (residual matrix, co-culture, inhibitors) that must be reviewed.

Practical notes that accelerate feasibility review:

• Whether the pellet contains residual extracellular matrix (and whether wash steps were performed)
• Whether organoids are derived from tumor vs normal tissue
• Passage number and culture conditions if they might affect cellular composition

Tumor and adjacent normal organoid lines

Answer: paired tumor/adjacent normal organoid lines are often helpful for RUO experimental design, but they increase quote complexity because they double sample sets and may require stricter labeling and metadata.

If you are requesting 100/200/143-sample quotes, call out explicitly:

• Whether samples are paired (tumor/normal)
• Whether pairing must be preserved in reporting and downstream analysis

Cell pellets vs extracted DNA

Answer: if you can provide extracted genomic DNA with QC, you often reduce quote ambiguity and shorten feasibility review. If you provide pellets, extraction variability becomes a major unknown.

A practical compromise is to ask for a split submission in the feasibility stage:

• a subset as extracted DNA with QC
• the remainder as pellets for extraction under an agreed plan

Whole blood and cohort samples

Answer: whole blood can be considered for long-read HLA typing (RUO), especially for cohort-scale donor research screening designs, but it requires careful handling, consistent labeling, and a metadata plan. For large cohorts, most delays are operational (sample identity, crosswalks, missing fields), not sequencing.

Whole blood (RUO screening use case)

If your project is a donor research screening study, write it that way: "RUO cohort genotyping/typing study," not clinical eligibility or donor matching.

What the service team typically needs to confirm:

• Whether DNA extraction is needed and whether extraction will preserve integrity
• Whether samples are processed across multiple sites (risk of inconsistent pre-analytics)

Planning for 100/200/143-sample requests

When quotes involve triple-digit cohorts, you want to remove ambiguity up front:

• Provide a sample sheet with consistent IDs
• Declare expected batch sizes and shipping cadence
• State whether samples are all the same format (e.g., whole blood) or mixed

A useful non-commercial framing for why this matters: EMBL-EBI's BioSamples work emphasizes structured, FAIR sample metadata and stable identifiers as a backbone for reusable genomics datasets (see BioSamples database paper, 2021, PMC). Even if your project isn't a public deposition, the same discipline reduces errors and rework.

For shipping and labeling conventions, align early with the CD Genomics sample submission guideline.

What information is needed before requesting a quote?

Answer: for long-read HLA typing, a quote is usually blocked by missing information in five areas: sample format, sample count, target loci, desired resolution, and DNA availability/extraction needs. If you supply those clearly—plus any QC and cohort metadata—you reduce back-and-forth and get a more reliable feasibility assessment.

Table 2. Sample issue → possible impact on long-read HLA typing → mitigation

Use this table to troubleshoot your quote request before you send it: if you recognize your project in one of the left-column issues, include the mitigation details in the first email.

Table 3. Quote-readiness checklist (copy/paste)

Use this checklist as your "quote minimum dataset." If you can fill every row, most long-read HLA typing quotes can move from "questions back" to "feasibility review started" quickly.

Common sample-submission mistakes

Answer: the most common delays aren't exotic biology—they're missing scope and missing provenance. If you want to avoid a two-week email loop, avoid these patterns.

1. Not stating the number of samples up front (or changing it later)

• Why it matters: cohort design drives batching, QC workload, and feasibility assumptions.

2. Unclear loci and resolution expectations

• Why it matters: "HLA typing" can mean different locus scopes and different reporting granularity.

3. Assuming FFPE is always acceptable for long-read needs

• Why it matters: FFPE damage is variable; long-read benefit is integrity-dependent.

4. Sending extracted DNA without QC context

• Why it matters: quantity alone doesn't predict read-length distribution.

5. Not clarifying extraction responsibility

• Why it matters: extraction workflow (and cleanup) changes feasibility and timelines.

6. Using clinical wording in an RUO service context

• Why it matters: it can trigger compliance review and misaligned expectations. Keep the request strictly research-scoped.

Research-use-only limitations

Answer: long-read HLA typing services described here are for research use only. Results should be interpreted as research findings and used within appropriate study designs, not for clinical decisions.

What this means in practice:

• Do not request (and do not expect) clinical donor eligibility decisions, transplant matching, patient management, or regulated diagnostic claims.
• The service team may require project review to ensure the requested scope stays within RUO boundaries.
• "High resolution" in research workflows is not a guarantee of clinical-grade interpretation.

FAQ

Can HLA typing be performed from FFPE blocks?

Yes, HLA typing from FFPE may be considered in some RUO contexts, but FFPE is not a "default" input for long-read workflows. FFPE processing often fragments and chemically damages DNA, which is a known limitation for long-range amplification and long-read sequencing. For a quote, expect a feasibility review and potentially a pilot extraction/QC step. If your project depends on long contiguous coverage across HLA loci, include that requirement explicitly so the feasibility review can focus on integrity risk.

Can CD Genomics extract DNA from FFPE blocks or should I provide DNA?

In many cases, you can request DNA extraction support as part of a feasibility review, but you should not assume FFPE extraction will automatically yield DNA suitable for long-read HLA typing. The limiting factor is typically integrity and chemical damage, not whether extraction is possible at all. If you already have extracted DNA plus integrity QC, that can speed quoting. If you don't, be prepared to share block age and any fixation details you have, and to discuss whether a pilot extraction/QC step is appropriate.

How many T cells are needed for HLA typing?

There isn't a single universal T-cell number that applies to every long-read HLA typing workflow, because requirements depend on extraction method, DNA yield, integrity, and the scope of loci/resolution requested. For a quote, the service team generally needs to know whether you are providing a frozen pellet, how the T cells were enriched, and whether you require matched comparators. Exact input expectations should be confirmed with the CD Genomics service team during project review.

Can frozen organoid pellets be used?

Frozen organoid pellets may be considered, but feasibility depends on what's in the pellet besides cells. Residual extracellular matrix, co-culture components, and inhibitors can complicate extraction and downstream library prep. The quote will also depend on whether you're submitting tumor organoids, normal organoids, or paired sets, because pairing affects sample counts and reporting structure. If you can provide pellet handling details (wash steps, freezing medium, passage information) and whether matched normal is available, you'll significantly reduce back-and-forth and improve the accuracy of the feasibility assessment.

Can whole blood be used for donor research screening?

Whole blood can be considered for RUO cohort screening designs, but the request should be framed strictly as research—not clinical donor eligibility or transplant matching. For quoting, clarify handling time/temperature, whether collection is centralized vs multi-site, and the batch plan. If you want to reduce delays, treat sample identity and metadata as a first-class deliverable (stable IDs, crosswalks, and a complete sample sheet).

What input DNA amount is required?

Exact DNA input requirements depend on the assay strategy, target loci, and sequencing platform/library preparation choices, so it should be confirmed during feasibility review rather than assumed from generic rules. Conceptually, long-read approaches benefit from highly purified, high-molecular-weight DNA; fragmented DNA can reduce the fraction of long reads and impact phasing advantages.

What information is needed for a rough quote?

For a rough quote, the minimum dataset is: sample type, number of samples, requested HLA loci, desired resolution, and whether genomic DNA is already extracted. Add any known preservation details (especially for FFPE, organoids, or multi-site cohorts) and any DNA QC you already have. If you can also specify whether you need DNA extraction support and what deliverables you expect (typing report only vs added analysis), you'll get a more accurate scope assessment.

Is this service suitable for clinical donor matching?

No. This article and the associated long-read HLA typing discussion are for research use only. They are intended to support feasibility assessment, study design, and RUO data interpretation—not clinical donor eligibility, transplant matching, patient management, or regulated diagnostic use.

Next steps

For service details and workflow context, see the CD Genomics long-read HLA typing service page.

If you also need a plain-language explanation of why long reads help with complex loci and phasing, the CD Genomics overview on long-read vs short-read sequencing is a helpful background reference.

Send your sample type, sample number, requested HLA loci, desired resolution, DNA availability, and extraction needs to request a long-read HLA typing feasibility review.

Author

Dr. Yang H.
Senior Scientist at CD Genomics
LinkedIn: Dr. Yang H. on LinkedIn

Dr. Yang H.'s work at CD Genomics focuses on long-read sequencing study support and bioinformatics-aware sample planning, including evaluating DNA integrity and pre-analytical constraints that influence the feasibility of high-resolution HLA typing workflows in research settings.